SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug ...
Endpoints News, the biopharma industry’s source for breaking news, exclusive reporting and smart analysis, today unveiled this year’s Endpoints 11 winners — honoring 2025’s most exciting biotech ...
(RTTNews) - Akeso Inc. reported positive results from Phase 3 clinical trial of gumokimab or AK111, a fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback